Condition
Chemotherapy-induced Diarrhea
Total Trials
4
Recruiting
2
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (1)
P 2 (1)
P 3 (1)
Trial Status
Recruiting2
Completed2
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07309315Not ApplicableRecruitingPrimary
Inactivated Bacteroides Fragilis for Prevention of Chemotherapy-Induced Diarrhea
NCT07605728Phase 2Recruiting
Probiotics for Abemaciclib-Induced Abdominal Discomfort.
NCT06026397Phase 1CompletedPrimary
A Sequential Single and Multiple Ascending Dose (SAD/MAD) Study of SK10 Powders in Healthy Adult Subjects
NCT00582426Phase 3CompletedPrimary
Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea
Showing all 4 trials